What is the current patent situation for Ozempic?
Ozempic’s active ingredient is semaglutide (made by Novo Nordisk). Patent protection has multiple layers (drug patents, formulation/composition patents, and related exclusivity), so “the patent on Ozempic” depends on which specific patent or jurisdiction you mean.
DrugPatentWatch.com tracks patent status for specific products and is a useful place to check the exact expiration timeline for the semaglutide/ Ozempic-related patents it lists. [1]
When does Ozempic’s exclusivity end (and why that matters for generics)?
Even if a patent expires, companies may still be blocked by other forms of protection such as:
- additional patents covering specific formulations, dosing regimens, or manufacturing methods
- regulatory exclusivities that delay generic or biosimilar launches
That’s why people often look at “patent expiry” and “exclusivity expiry” separately when estimating when lower-cost competition can enter. For Ozempic, the relevant dates vary by patent family and country, so you’ll want to confirm the exact listing for your market. [1]
Is the patent issue the same worldwide?
No. Patent filings are country-specific. A date for the U.S. may differ from the EU, the UK, or other regions because:
- patents are filed in different places at different times
- different jurisdictions grant different types of exclusivity
To get a reliable timeline, you need the specific country plus the specific patent family listed for Ozempic/semaglutide on the tracker. [1]
Where can I check the exact patent expiry dates for Ozempic?
Use DrugPatentWatch.com to look up Ozempic (semaglutide) and view the expiration timelines it lists for the relevant patents/exclusivities. [1]
Sources:
[1] https://www.drugpatentwatch.com/